Advances in viral-vector systemic cytokine gene therapy against cancer

Vaccine

Volumn 28, Issue 23, 2010, Pages 3883-3887

  Liu, Lihua ^a   Wang, Shijie ^a   Shan, Baoen ^a   Sang, Meixiang ^a   Liu, Shuang ^a   Wang, Guiying ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Cytokine; Gene therapy; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CYTOKINE; FLUOROURACIL; H 101; INTERLEUKIN 2; INTERLEUKIN 4; LENTIVIRUS VECTOR; MIDKINE; ONCOLYTIC ADENOVIRUS; ONCORINE; ONYX 015; PROTEIN P53; RETROVIRUS VECTOR; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL BASED GENE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DENDRITIC CELL; ESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; LUNG CANCER; MELANOMA; MESENCHYMAL STEM CELL; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RECTUM CANCER; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STROMA CELL; THROMBOEMBOLISM; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; RETROVIRIDAE;

EID: 77952423756     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.041     Document Type: Review

References (60)

1. Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.T., and Rosenberg S.A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256 (1986) 3117-3124
2. Shau H., Isacescu V., Ibayashi Y., Tokuda Y., Golub S.H., Fahey J.L., et al. A pilot study of intralymphatic interleukin-2, I. Cytotoxic and surface marker changes of peripheral blood lymphocytes. J Biol Response Mod 9 (1990) 71-80
3. Ozer H., Wiernik P.H., Giles F., and Tendler C. Recombinant interferon-alpha therapy in patients with follicular lymphoma. Cancer 82 (1998) 1821-1830
4. Motzer R.J., Rakhit A., Schwartz L.H., Olencki T., Malone T.M., Sandstrom K., et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4 (1998) 1183-1191
5. Hao J.S., and Shan B.E. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother 55 (2006) 1426-1431
6. WaltherW, Stein U., Voss C., Schmidt T., Schleef M., and Schlag P.M. Stability analysis for long-term storage of naked DNA impact on nonviral in vivo gene transfer. Anal Biochem 318 (2003) 230-235
7. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158 (1992) 97-129
8. Kreiss P., Cameron B., Rangara R., Mailhe P., Aguerre-Charriol O., Airiau M., et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 27 (1999) 3792-3798
9. Li Q., Kay M.A., Finegold M., Stratford-Perricaudet L.D., and Woo S.L. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 4 (1993) 403-409
10. Quantin B., Perricaudet L.D., Tajbakhsh S., and Mandel J.L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 89 (1992) 2581-2584
11. Engelhardt J.F., Ye X., Doranz B., and Wilson J.M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91 (1994) 6196-6200
12. Crowther C., Ely A., Hornby J., Mufamadi S., Salazar F., Marion P., et al. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther 19 (2008) 1325-1331
13. Sorensen M.R., Holst P.J., Pircher H., Christensen J.P., and Thomsen A.R. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 39 (2009) 2725-2736
14. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53- deWcient human tumor cells. Science 274 (1996) 373-376
15. O'Shea C.C., Saria C., Bagus B., and McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015oncolytic viral therapy. Cancer Cell 8 (2005) 61-74
16. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6 (2004) 611-623
17. You L., Yang C.T., and Jablons D.M. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60 (2000) 1009-1013
18. He X.P., Su C.Q., Wang X.H., Pan X., Tu Z.X., Gong Y.F., et al. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett 285 (2009) 89-98
19. Shiina M., Lacher M.D., Christian C., and Korn W.M. RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther 16 (2009) 810-819
20. Takei Y., Kadomatsu K., Matsuo S., Itoh H., Nakazawa K., Kubota S., et al. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61 (2001) 8486-8491
21. Xu Y., Qu X., Zhang X., Luo Y., Zhang Y., Luo Y., et al. Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett 279 (2009) 137-144
22. Yu L., Hamada K., Namba M., Kadomatsu K., Muramatsu T., Matsubara S., et al. Midkine promoter-driven suicide gene expression and-mediated adenovirus replication produced cytotoxic effects to immortalized and tumour cells. Eur J Cancer 40 (2004) 1787-1794
23. Tsuruta Y., Pereboeva L., Breidenbach M., Rein D.T., Wang M., Alvarez R.D., et al. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 14 (2008) 3582-3588
24. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65 (2005) 3307-3318
25. Van de Ven R., Lindenberg J.J., Oosterhoff D., van den Tol M.P., Rosalia R.A., and Murakami M. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J Immunother 32 (2009) 895-906
26. Wei C.M., Gibson M., Spear P.G., and Scolnick E.M. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol 39 (1981) 935-944
27. Shimotohno K., and Temin H.M. Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 26 (1981) 67-77
28. Wang H., Yang G., Timme T.L., Fujita T., Naruishi K., Frolov A., et al. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 14 (2007) 819-827
29. Liu L., Wang S., Shan B., Shao L., Sato A., Kawamura K., et al. IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J Immunol 68 (2008) 22-29
30. Liu L., Shan B., and Feng Y. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell Immunol 258 (2009) 181-187
31. Fillat C., Carrió M., Cascante A., and Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 3 (2003) 13-26
32. Miller D.G., Adam M.A., and Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10 (1990) 4239-4242
33. Trobridge G.D., Beard B.C., Gooch C., Wohlfahrt M., Olsen P., Fletcher J., et al. Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood 111 (2008) 5537-5543
34. Indraccolo S., Habeler W., Tisato V., Stievano L., Piovan E., Tosello V., et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res 62 (2002) 6099-6107
35. Pang S., Kang M.K., Kung S., Yu D., Lee A., Poon B., et al. Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin Cancer Res 7 (2001) 3567-3573
36. Solly S.K., Trajcevski S., Frisén C., Holzer G.W., Nelson E., Clerc B., et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 10 (2003) 30-39
37. Kusumoto M., Umeda S., Ikubo A., Aoki Y., Tawfik O., Oben R., et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 50 (2001) 373-381
38. Duval L., Schmidt H., Kaltoft K., Fode K., Jensen J.J., Sorensen S.M., et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 12 (2006) 1229-1236
39. Fong L., Kwek S.S., O'Brien S., Kavanagh B., McNeel D.G., Weinberg V., et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69 (2009) 609-615
40. Tani K., Azuma M., Nakazaki Y., Oyaizu N., Hase H., Ohata J., et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther 10 (2004) 799-816
41. Uemura H., Fujimoto K., Tanaka M., Yoshikawa M., Hirao Y., Uejima S., et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12 (2006) 1768-1775
42. Arienti F., Belli F., Napolitano F., Sulé-Suso J., Mazzocchi A., Gallino G.F., et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 10 (1999) 2907-2916
43. Osanto S., Schiphorst P.P., Weijl N.I., Dijkstra N., Van Wees A., Brouwenstein N., et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 11 (2000) 739-750
44. Maio M., Fonsatti E., Lamaj E., Altomonte M., Cattarossi I., Santantonio C., et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 51 (2002) 9-14
45. Rochlitz C., Dreno B., Jantscheff P., Cavalli F., Squiban P., Acres B., et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 9 (2002) 289-295
46. Tartour E., Mehtali M., Sastre-Garau X., Joyeux I., Mathiot C., Pleau J.M., et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer 83 (2000) 1454-1461
47. Fujii S., Huang S., Fong T.C., Ando D., Burrows F., Jolly D.J., et al. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther 7 (2000) 1220-1230
48. Qian C., and Prieto J. Gene therapy of cancer: induction of anti-tumor immunity. Cell Mol Immunol 1 (2004) 105-111
49. Griscelli F., Opolon P., Saulnier P., Mami-Chouaib F., Gautier E., Echchakir H., et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 10 (2003) 386-395
50. Trudel S., Trachtenberg J., Toi A., Sweet J., Li Z.H., Jewett M., et al. A phase I trial of adenovectormediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 10 (2003) 755-763
51. Stewart A.K., Lassam N.J., Quirt I.C., Bailey D.J., Rotstein L.E., Krajden M., et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 6 (1999) 350-363
52. Lenzi R., Edwards R., June C., Seiden M.V., Garcia M.E., Rosenblum M., et al. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5 (2007) 66
53. Rasmussen H., Rasmussen C., Lempicki M., Durham R., Brough D., King C.R., et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiationinducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9 (2002) 951-957
54. Lopez C.A., Kimchi E.T., Mauceri H.J., Park J.O., Mehta N., Murphy K.T., et al. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 3 (2004) 1167-1175
55. Gregorc V., Santoro A., Bennicelli E., Punt C.J., Citterio G., Timmer-Bonte J.N., et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 101 (2009) 219-224
56. Mundt A.J., Vijayakumar S., Nemunaitis J., Sandler A., Schwartz H., Hanna N., et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10 (2004) 5747-5753
57. Chung T.D., Mauceri H.J., Hallahan D.E., Yu J.J., Chung S., Grdina W.L., et al. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther 5 (1998) 344-349
58. Murugesan S.R., King C.R., Osborn R., Fairweather W.R., O'Reilly E.M., Thornton M.O., et al. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 16 (2009) 841-847
59. Mezhir J.J., Smith K.D., Posner M.C., Senzer N., Yamini B., Kufe D.W., et al. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther 13 (2006) 1-6
60. Kirn D.H. The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept. Mol Ther 13 (2006) 237-238